DGAP-News

Neovacs S.A.: Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship - Seite 4

"anticipate," "believe," "plan," "estimate," "expect," "intend," "may,"
"will," "would," "could," "should," "might," "potential," or "continue" and
variations or similar expressions. Readers should not unduly rely on these
forward-looking statements, which are not a guarantee of future
performance. There can be no assurance that forward-looking statements will
prove to be accurate, as all such forward-looking statements involve known
and unknown risks, uncertainties and other factors which may cause actual
results or future events to differ materially from the forward-looking
statements. Such risks include, but may not be limited to: general economic
and business conditions; technology changes; competition; changes in
strategy or development plans; governmental regulations and the ability or
failure to comply with governmental regulations; the timing of anticipated
results; and other factors referenced in the Company's filings with
securities regulators. For a discussion of further risks and uncertainties
related to the Company's business, please refer to the Company's public
company reports filed with the TSX Venture Exchange and the U.S. Securities
and Exchange Commission. All forward-looking statements are made as of the
date hereof and are subject to change. Except as required by law, the
Company assumes no obligation to update such statements. This press release
does not constitute an offer or solicitation of an offer for sale of any
securities in any jurisdiction, including the United States. Neither the
TSX Venture Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of the information contained in this press
release.



---------------------------------------------------------------------

01.04.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: Neovacs S.A.
3-5, Impasse Reille
75014 Paris
France
Phone: [phone]
Fax: [phone]
E-mail: www.neovacs.fr
Internet: [e-mail]
ISIN: FR0004032746
WKN: A1CVKR
Listed: Regulated Unofficial Market in Stuttgart; Open Market in
Frankfurt


End of News DGAP News-Service
---------------------------------------------------------------------
339839 01.04.2015